August 2003 in “药物不良反应杂志” Combining finasteride and terazosin can cause severe allergic reactions.
1 citations
,
October 2013 in “Urology” More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
January 2025 in “Current Trends in Pharmacy and Pharmaceutical Chemistry” New methods for measuring dutasteride are effective and reliable.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
2 citations
,
September 2025 in “Frontiers in Endocrinology” SARMs show promise but need more evidence to prove they're better than traditional androgens.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
September 2025 in “Reactions Weekly” January 2020 in “Journal of Men s Health” The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
May 2025 in “Birth Defects Research” YWS1903 is safe for pregnant rats at moderate doses but causes fetal issues at high doses.
19 citations
,
December 2008 in “Arthritis Care & Research” The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
18 citations
,
October 2020 in “Journal of Pharmacology and Experimental Therapeutics” KATP channel openers may cause peripheral edema by reducing lymphatic contractions and flow.
January 1993 in “Journal of International Medical Research” The document corrects errors in previous articles, including a reversed term, updated subject weights, hair count data, and reference numbering.
11 citations
,
August 2009 in “Expert Opinion on Drug Discovery” We need better ways to test and understand SARMs to make safer and more effective treatments.
90 citations
,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
June 2026 in “Frontiers in Medicine” This systematic review examines the sexual dysfunction associated with 5α-reductase inhibitors (5-ARIs) used for treating androgenetic alopecia (AGA). Analyzing 41 studies, it finds that sexual adverse events, such as decreased libido and erectile dysfunction, occur in 1.9–6.7% of men taking oral finasteride and 4.1–12.0% for dutasteride, with lower rates for topical finasteride. These effects are generally mild, reversible, and not consistently reported in women. Clinicians should inform patients about these potential side effects, emphasizing their infrequency and reversibility, while advocating for shared decision-making and further research to better understand individual susceptibility and long-term risks.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
2 citations
,
January 2020 in “Yonsei Medical Journal” Dutasteride for hair loss might increase the risk of a rare stroke type.
8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
3 citations
,
October 2021 in “Turkish Journal Of Neurology” Genetic analysis is crucial for diagnosing and managing cerebral arteriopathy.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
The new gel for hair loss is safe, effective, and reduces side effects.
July 2023 in “Assiut Veterinary Medical Journal/Maǧallaẗ Asyūṭ al-ṭibiyyaẗ al-baytariyyaẗ” Antiandrogens help improve developmental delays caused by valproic acid in rats.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
September 2004 in “Urology” Dutasteride may help prevent prostate cancer, but more research is needed.
2 citations
,
September 2025 in “Journal of Dermatological Treatment” Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.